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Abstract: The autoimmune thyroid diseases (AITD) include Graves’ disease (GD) and Hashimoto’s thyroiditis (HT), 
which are characterised by a breakdown in immune tolerance to thyroid antigens. Unravelling the genetic architecture of 
AITD is vital to better understanding of AITD pathogenesis, required to advance therapeutic options in both disease 
management and prevention. The early whole-genome linkage and candidate gene association studies provided the first 
evidence that the HLA region and CTLA-4 represented AITD risk loci. Recent improvements in; high throughput 
genotyping technologies, collection of larger disease cohorts and cataloguing of genome-scale variation have facilitated 
genome-wide association studies and more thorough screening of candidate gene regions. This has allowed identification 
of many novel AITD risk genes and more detailed association mapping. The growing number of confirmed AITD 
susceptibility loci, implicates a number of putative disease mechanisms most of which are tightly linked with aspects of 
immune system function. The unprecedented advances in genetic study will allow future studies to identify further novel 
disease risk genes and to identify aetiological variants within specific gene regions, which will undoubtedly lead to a 
better understanding of AITD patho-physiology.  
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INTRODUCTION 
  The complete spectrum of autoimmune diseases affect 
the majority of tissues within the body, including, for 
example, pancreatic beta cells in type 1 diabetes (T1D), 
synovial joint antigens in Rheumatoid Arthritis (RA) and 
myelin surrounding nerve axons in Multiple sclerosis (MS) 
[1, 2]. Although the epidemiology varies according to 
individual conditions, collectively, autoimmune prevalence 
is at least 5% in the general population and is one of the 
major causes of premature mortality in young and middle 
aged women [2, 3]. By far the most common are the 
autoimmune thyroid diseases (AITDs) [2, 4], which include 
Graves’ disease (GD) and Hashimoto’s thyroiditis (HT), 
both characterised by lymphocytic infiltration of the thyroid 
with autoantibodies targeting thyroid antigens, including 
thyroid peroxidise (predominantly in HT), thyroglobulin 
(Tg) and the thyroid stimulating hormone receptor (TSHR) 
[5, 6]. Despite a similar autoantibody profile GD and HT 
display distinct clinical phenotypes. Lymphocytic infiltration 
in HT ultimately leads to thyroid cell destruction and 
hypothyroidism [5]. In contrast the net effect in GD is 
usually autoantibody stimulation of the TSHR, independent 
of its ligand thyroid stimulating hormone (TSH), resulting in 
hyperthyroidism [6]. Both diseases are typical multifactorial 
disorders with a complex aetiology involving both genetic 
and environmental factors, with twin studies suggesting that 
up to 80% of risk may be attributed to genetic factors [7, 8]. 
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  The well documented co-clustering of autoimmune 
diseases within families and individuals, together with 
apparent sharing of a number of disease risk genes (Fig. 1)
[9-12] suggests at least some common disease mechanisms. 
Improving our understanding of AITD pathophysiology 
could lead to better therapeutic options not only for disease 
management and/or predictive models for AITD but could 
also have implications for other autoimmune disorders. 
Genetic studies over the last 20 years have aimed to identify 
loci that confer susceptibility to AITD as a strategy to better 
understand the underlying biology behind disease. During 
this time numerous advances have been made in our 
understanding of AITD genetics, particularly in GD. This 
review will provide a brief background of AITD genetics, 
followed by a more detailed examination of AITD risk genes 
that have recently been more extensively mapped for 
association with GD. This will be followed by an assessment 
of more recent disease gene discovery efforts, with a final 
broad overview of pathways involved in GD pathogenesis 
uncovered through genetic studies. 
EARLY DAYS OF AITD GENE DISCOVERY  
  Initial efforts to identify disease risk genes employed 
both, family-based linkage studies, examining the co-
inheritance of microsatellite markers (1-6bp tandem repeat 
sequences) between affected and non-affected family 
members, and candidate gene association studies in which 
the frequency of di-allelic single nucleotide polymorphisms 
(SNPs) were analysed in unrelated disease affected cases and 
unaffected controls. Both approaches were initially 
hampered because of inadequate knowledge of human 
genetic variation, undersized study cohorts and a lack of high Immunogenetic Mechanisms Leading to Thyroid Autoimmunity  Current Genomics, 2011, Vol. 12, No. 8    527
throughput genotyping methodologies with a general 
reliance upon PCR amplification followed by restriction 
enzyme digestion. A major step forward was the first 
detailed linkage map of microsatellite markers across the 
entire human genome heralding a new era of large-scale, 
genome-wide linkage studies, which it was hoped would 
yield novel disease susceptibility genes in complex disease 
[13]. 
  The first linkage study performed in a complex genetic 
disorder was in T1D [14, 15], shortly followed by linkage 
analysis in most multifactorial diseases, including AITD [16-
20]. Despite the successful use of linkage studies to identify 
rare and highly penetrant mutations in monogenic disorders, 
such as cystic fibrosis [21] and maturity-onset diabetes of the 
young [22, 23] this approach largely failed to deliver novel 
susceptibility loci in AITD. The first linkage study in AITD 
consisted of 56 multiplex Caucasian family members 
(families with either GD or HT as well as unaffected 
members) and identified linkage at 7 regions, 3 were GD 
specific termed, GD-1 (14q31) (GD-1 locus displayed in Fig. 
2A), GD-2 (20q11.2), GD-3 (Xp21), 2 in HT called HT-1 
(13q32) and HT-2 (12q22) and one common AITD locus, 
AITD-1 (6p11) [16]. Further investigation using the same 
cohort with 46 additional families (102 total) failed to 
replicate linkage at three of these loci, Xp21, 13q32, 20q11.2 
and signals detected at 6p11 and 14q31 were detected many 
centimorgans (cM) distant from the original markers, raising 
concerns over reproducibility of results [17, 24]. The largest 
AITD genome linkage screen to date investigated 389 
microsatellite markers in 1119 Caucasian AITD relative 
pairs from the UK, continental Europe and Australasia 
revealing suggestive evidence of linkage with multi-point 
logarithm of odds (LOD) scores between 2 and 3 at 
chromosomes 18p11, 2q36 and 11p15 [18], but failed to 
replicate the previous loci [16]. Chromosome 5q31-q33 
identified by independent linkage studies in Japanese and 
Chinese cohorts represented the most convincing evidence 
that an AITD predisposing gene might be located within the 
region [19, 20]. A study in 123 Japanese sib-pairs 
investigated 392 microsatelite markers across the genome 
and identified the strongest multipoint LOD score of 3.14 at 
D5S436 within 5q31-q33 [19]. This was subsequently 
replicated in 54 Han Chinese multiplex families producing a 
LOD score of 2.8 for D5S436 [20]. Investigation of four 
additional markers surrounding D5S436 identified strongest 
linkage at nearby D5S2090 giving a 2-point LOD score of 
4.31 [20]. With the exception of 5q31-q33 the majority of 
signals detected in all studies fell below linkage LOD scores 
acceptable for genome-wide significance (LOD>3) 
highlighting the uncertainty in results produced [15]. 
Furthermore, the low coverage of linkage maps meant the 
physical genomic distance between markers was large 
making it very difficult to determine the causal gene in a 
region of linkage. In retrospect failure to identify now well 
recognised susceptibility genes or regions such as HLA, 
CTLA-4 and PTPN22 reflects the disappointing application 
of this approach. These studies suggest that in AITD, like 
most other complex diseases, there are unlikely to be any or 
at least very few causal or highly penetrant common variants 
that directly induce AITD in certain individuals. 
  Association studies inherently have greater power to 
detect a disease-risk gene, since greater numbers of SNPs 
Fig. (1). Sharing of susceptibility genes among the Autoimmune diseases, Graves’ disease, Multiple sclerosis and Type 1 diabetes. The
figure shows disease risk genes that are unique to the 3 individual diseases and those shared between either two of the diseases or all three 
disorders.
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can be investigated in a single region and large, well-
powered case-control cohorts are more easily collected. The 
limitation however, is that a causal variant must be either 
directly interrogated or a neighbouring marker that is 
strongly correlated with the aetiological variant be tested to 
detect association. Before the arrival of improvements that 
would later facilitate genome-wide association studies 
(GWAS), researchers investigated candidate gene regions, 
often focusing on small numbers of variants where 
functional effects could be more easily translated, such as 
non-synonymous (amino acid altering) SNPs (nsSNPs) or 
those located in 3’ or 5’ regulatory regions [25-27]. 
Accumulation of data from multiple studies gradually 
provided convincing evidence for two AITD susceptibility 
loci; HLA and CTLA-4 [27-32]. For more than 30 years 
evidence suggested the HLA region on 6p21 predisposed to 
autoimmune diseases [33-35], although early studies 
provided inconclusive evidence of association with GD [36-
41]. However, studies eventually provided good evidence 
that alleles within the HLA class II region were strongly 
associated with GD [28, 29]. Further investigations have 
since refined the major association signals to genes within 
the HLA class I region, HLA-C and HLA-B [42] and the 
HLA class II region genes DRB1 and DQA1  [43, 44]. 
Evidence of CTLA-4 association with GD was demonstrated 
by a number of studies investigating common functional 
variants, including a dinucleotide (AT)n repeat within the 3’ 
UTR [27], a single SNP in the promoter region 318bp 
upstream of the start codon [31], an exon 1 SNP [30] and a 
non-coding intron 1 variant [32]. Comprehensive fine-
mapping of the CD28-CTLA-4-ICOS region has since 
refined the association signal to within a 6.1Kb region, 3’ of 
CTLA-4, with 4 SNPs being strong aetiological candidates 
[9]. Despite these two successes, investigating a limited 
number of variants in a given region led to some genes being 
incorrectly ruled non-associated with AITD, such as the 
TSHR, which was later confirmed as being associated in 
more recent detailed investigations.  
LATER DAYS OF AITD GENE DISCOVERY AND 
REFINING ASSOCIATION SIGNALS 
  Completion of the first human genome sequence just 
more than a decade ago provided a reference to begin 
cataloguing the true extent of genetic variation, much needed 
for improved disease gene discovery. The International 
HapMap Project represented the first major undertaking, 
which characterised 3.5 million common SNP allele 
frequencies and the correlation between them or linkage 
disequilibrium (LD) in several ethnic populations 
(www.hapmap.org). LD can be defined as the naturally 
occurring, non-random clustering of alleles at neighbouring 
SNPs. LD mapping across the entire human genome has 
enabled researchers to carefully select a series of tag SNPs 
that capture the genetic variation of correlated un-typed 
SNPs and thus remove the need to genotype every SNP in a 
given region [45-49]. Further developments in genotyping 
technology, moving from PCR-RFLP based methods to 
faster and more cost effective fluorescent probes has enabled 
larger numbers of SNPs to be interrogated in a single study. 
In addition, collection of larger AITD cohorts by several 
investigators provided greater power to detect regions of 
association, which was important, considering the modest 
magnitudes of effect anticipated (OR=1.2-1.5) [50-52]. 
These advances have facilitated comprehensive SNP 
screening and enabled both novel disease gene identification 
and refining of association signals by interrogating a dense 
set of common SNPs to narrow down the location of the 
aetiological variant. Notable examples include the TSHR,
SCGB3A2, PTPN22, and IL2R .
TSHR 
 The  TSHR encodes the primary autoantigen in GD and as 
such represents a prime candidate gene. Interestingly, a 
number of microsatellite markers that define a 25cM region 
of linkage to GD, termed GD-1, encompasses the TSHR as 
well as a number of other plausible candidate genes (Fig. 2)
[16, 17, 24, 53, 54]. Several early association studies on 
TSHR nsSNPs were performed, however these provided 
conflicting evidence of TSHR association with GD [55]. 
More convincing evidence of TSHR association with GD, 
but not HT, came from independent tag SNP screens in 
Japanese and Caucasian cohorts, which identified two 
overlapping signals [56, 57]. Twenty two TSHR intronic 
SNPs investigated in 401 AITD patients (250 GD and 151 
HT) and 238 controls of Japanese descent identified several 
individual SNP and haplotype associations across the region 
[57]. Strongest SNP associations were located within intron 
7 of the TSHR (P=10
-2-10
-4) [57]. In contrast, 20 SNPs 
spanning an extended 600Kb of the TSHR were analysed in a 
multinational Caucasian cohort, which identified 10 SNP 
associations located across a wide 340Kb region 
encompassing TSHR intron 1 and the neighbouring 5’ 
C14ORF145, approximately 140Kb upstream of the main 
signal identified in Japanese [56]. More recently a panel of 
98 SNPs selected across 800Kb encompassing C14ORF145-
TSHR-STN2-GTF2A1 were investigated in 768 UK 
Caucasian GD cases and controls [58] (Fig. 2). Numerous 
SNP associations were identified, with SNPs rs179247 and 
rs12101255 demonstrating strongest evidence of association 
with GD, and which are located within a distinct 40Kb of 
TSHR intron 1 [58]. These variants have since been further 
replicated in independent UK and Polish case-control 
cohorts (P=10
-15 – 10
-21 and odds ratios (OR) = 1.38 – 1.87), 
with logistic regression suggesting that the aetiological 
variant is most likely to be in strong LD with rs12101255 
[50] (Fig. 2). All variants within and just outside the 40Kb 
region of TSHR intron 1 now require detailed investigation 
to identify the aetiological variant within the region. 
SCGB3A2
  Replicated in two independent linkage studies, the 
previously discussed chromosome 5q31-q33 region 
demonstrated the most convincing evidence of linkage in 
AITD [19, 20]. Across this region there are a number 
plausible AITD candidate genes, including; interleukin 12b 
(IL-12b) [59, 60], IL-13, IL-4 [61-63], interferon regulatory 
factor 1 (IRF1) and beta-2-adrenergic receptor (ADRB2)
[64], exemplifying the challenge involved in identifying a 
causal gene in a region of linkage. To locate the causal gene, 
Song and colleagues recently performed a comprehensive 
series of association screens to identify the Secretoglobin 
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screen of 179 SNPs encompassing 3Mb around the AITD 
linked marker, D5s2090, in 384 GD cases and controls from 
Shandong, China, identified  strongest SNP association 
(rs1368408) within the promoter of SCGB3A2 [51]. To 
refine association, a further 122 SNPs were identified by re-
sequencing and investigated in two independent Chinese 
case-control cohorts [51]. Strongest SNP association 
remained within the SCGB3A2 promoter SNP, rs1368408 
and a second neighbouring SNP (P=10
-5-10
-6, OR=1.28-1.32) 
in the combined Chinese cohort (2811 GD patients and 2807 
controls) [51]. Importantly the most highly associated SNP 
(rs1368408) has since been replicated in two independent 
Caucasian GD cohorts; the first from the UK National 
collection of AITD cases, consisting 2504 GD and 2688 
control from the 1958 British Birth Cohort (58c) (P=10
-3,
OR=1.18) and the second in 1474 GD and 1619 controls 
from Russia (P=10
-5, OR=1.33), confirming that SCGB3A2 
confers predisposition to GD [52, 65]. Although there is little 
doubt  SCGB3A2 is a genuine GD susceptibility locus, it 
remains possible other genes within the region may also 
confer an independent risk to GD. A recent study performed 
a tag SNP screen of 19 candidate genes within 5q31-q33 in 
428 GD cases and 690 controls of South Han Chinese 
descent [66]. Although SCGB3A2 was not one of the 19 
genes selected for analysis the study identified association 
with an IL-3 nsSNP (rs40401), which was subsequently 
replicated in a second independent Han Chinese cohort 
(P=10
-3-10
-4, OR=1.21-1.33), suggesting IL-3 might be a 
second susceptibility gene within the region [66]. 
PTPN22
  Accumulating evidence of shared susceptibility loci 
among the autoimmune diseases has directed a number of 
other gene discovery efforts in AITD, including PTPN22,
now a well-established general autoimmune risk locus. 
PTPN22 located on chromosome 1p13 encodes the cell 
signalling protein, lymphoid tyrosine phosphatase (LYP) 
which is a potent regulator of T cell activation [67]. The 
Fig. (2). Timeline of narrowing TSHR association with Graves’ disease. A. the GD-1 region of linkage spanning more than 25Mb of 
chromosome 14q. B. The shaded regions represent the boundaries of all SNP associations identified by Dechairo et al. [56] in a case-control 
cohort of international Caucasian decent and the boundaries of association identified by Hiratani et al. (2005) [57] in a Japanese cohort. C.
The highly associated 40Kb region within TSHR intron 1 with the two most strongly associated SNPs marked within the region (rs179247 
and rs12101255). Images were generated using the NCBI sequence viewer (http://www.ncbi.nlm.nih.gov).
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nsSNP located at 1858bp (C/T) within PTPN22 results in 
substitution of Arginine (Arg) (CGG) to a tryptophan (Trp) 
(TGG) at codon 620 (R620W) (rs2476601) and was first 
associated with T1D susceptibility in two independent case-
control cohorts of North American (P=10
-3) and Sardinian 
(P<0.05) background [68]. A follow up study confirmed 
PTPN22 R620W association in case-control and family T1D 
cohorts and provided the first evidence that PTPN22 was a 
general autoimmune risk locus by demonstrating strong 
association in 901 UK Caucasian GD and 833 ethnically 
matched controls (P=10
-4, OR=1.43) [69]. At the same time 
the 1858T allele was associated in an independent GD cohort 
(P=3.4x10
-5, OR=1.88) [70]. Further studies have replicated 
association with GD and have also identified association in 
HT patients [12] as well as in other autoimmune diseases, 
including RA and Systemic Lupus Erythematosus (SLE) [71, 
72]. While tag SNP screening in GD suggested effects 
independent of R620W [73], based on size of association 
compared to surrounding variants and functional studies 
performed it remains likely that R620W is the aetiological 
variant.  
IL2R 
  The interleukin-2 receptor alpha (IL2R )/CD25 gene was 
first investigated in T1D [11] and followed up in GD [10]. 
IL2R  encodes one of three proteins (the other 2 being IL-
2R  and IL-2R ) that make up the interleukin-2 receptor 
(IL-2R) important in lymphocyte function, particularly T 
regulatory cells (CD4
+ CD25
+ FOXP3
+ T cells) [74]. The 
first evidence that IL2R  confers susceptibility to T1D was 
demonstrated using a set of 20 tag SNPs across the gene 
region in large T1D case-control and family collections [11]. 
Using a multilocus test of association there was significant 
evidence for a T1D aetiological variant within the gene 
region (case-control P=6.5x10
-8) [11]. The multilocus test 
treats the SNPs collectively and so a measure of association 
is generated for the entire region, which can generate greater 
power to detect an association compared to investigating 
individual SNPs in a region [75, 76]. Based on these findings 
our group investigated the same set of tag SNPs across 
IL2R  in 1896 GD cases from the UK national collection 
and 1822 58c controls, identifying evidence of GD risk 
within the region (multilocus P=4.5x10
-4) [10]. 
Investigations in a Japanese GD cohort recently replicated 
IL2R  association in a single SNP (P=0.03) within the region 
[77]. Further studies are required to replicate association and 
to identify the aetiological variant in GD. Detailed fine-
mapping studies in T1D have since refined the association 
map to 2 independent groups of SNPs showing strong 
association with T1D (maximal P=10
-28, OR=2.04), the first 
within IL2R  intron 1 and the second located 5’ of IL2R 
upstream of neighbouring RBM17 [78]. The T1D associated 
alleles also demonstrated strong association with reduced 
soluble IL-2R  protein [78]. Variants in IL2R  are also 
predisposing in MS, albeit with different variants within 
intron 1 showing strongest association with disease [79, 80]. 
A recent comparison of T1D and MS association at IL2R 
demonstrated substantial discordance; with a T1D risk allele 
within intron 1 (rs41295061) not associated with MS, a T1D 
risk allele located 5’ of IL2R  (rs11594656) conferring 
protection from MS and a variant conferring risk to both 
diseases (rs2104286) [81]. Interestingly, all alleles whether 
conferring, predisposition or protection to T1D or MS, were 
associated with reduced soluble IL-2R  protein in both 
patient sub-groups [81]. The paradox in which alleles confer 
protection and predisposition, yet all influence soluble IL-
2R  protein in the same way is unclear without having a 
better understanding of the biological pathways involved. 
Similar heterogeneity between autoimmune diseases has also 
been observed in PTPN22, where the 1858T allele is 
associated with predisposition in T1D, GD, HT and RA, but 
confers protection in Crohn’s disease (CD) [82]. 
  A number of other loci have been identified through 
candidate gene approaches that are likely to be true GD, HT 
or combined AITD risk genes, including thyroglobulin (Tg) 
[83-86] and CD40 [87-89], however further studies are 
needed to refine the association signal in these regions. 
Many other regions have been implicated as conferring 
disease risk although require independent replication to 
confirm association, such as FOXP3 [90, 91] and VDR [92-
94]. For a complete list of implicated and confirmed AITD 
risk loci, refer to Table 1. Ultimately, candidate gene 
approaches are inherently limited by inadequate knowledge 
of the biological mechanisms and the function of proteins 
and/or non-coding RNAs encoded by the majority of genes 
across the genome. The arrival of genome-wide association 
studies (GWAS) now addresses these limitations and offers 
the potential to efficiently screen the genome for association 
in an unbiased, hypothesis free manner.  
BRAVE NEW WORLD – GWAS AND FOLLOW-UP IN 
OTHER AUTOIMMUNE DISEASES 
  The combination of advances in our understanding of 
genomic diversity, collection of large disease cohorts and 
genotyping technology meant the potential for GWAS could 
finally be realised. Using detailed LD maps generated by 
HapMap, it was estimated that in non-African populations, 
approximately 500,000 (500k) SNPs across the genome 
would be required to screen for association and capture 
approximately 80% of common genetic variation [95]. Many 
more SNPs are required to thoroughly screen African 
populations since they possess much greater genetic 
diversity, producing much smaller blocks of LD, and 
therefore, a greater number of SNPs are required to capture 
this variation. Technological advances in 500K SNP chips 
made genotyping this large number of variants in large 
disease cohorts more cost effective. In the past few years this 
has led to thousands of SNPs showing reproducible 
association in a diverse array of complex diseases and 
continuous traits (http://www.genome.gov/gwastudies). 
  To date there has not been a full 500K GWAS performed 
in AITD, although results from such a study would be 
eagerly received. As part of the Wellcome Trust Case 
Control Consortium (WTCCC) of investigators, our group 
performed a reduced-scale association screen of 14,500 
nsSNPs across the genome in 1,000 UK Caucasian GD 
cases, as well as the same number of breast cancer (BC), 
ankylosing spondylitis (AS) and MS cases with 1,500 shared 
58c controls [96]. Unsurprisingly, strongest GD associations 
were identified within the HLA-region (P<10
-20), which were 
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Table 1.  Shows Both Confirmed Graves’ disease Susceptibility Loci and Regions Requiring Further Confirmation of Association. 
Table Adapted from Simmonds and Gough (2011) [166] 
Chromosome Gene/Region  References 
Confirmed GD Susceptibility Loci 
6p21  HLA Class II  Heward et al. (1998) [28], Chen et al. (2000) [29], Ban et al. (2004) [44], Simmonds et al. (2005) [43], 
Wongsurawat et al. (2006) [135] 
6p21  HLA Class I  Farid et al. (1976) [136], Grumet et al. (1974) [137], Mather et al. (1980) [138], Huang et al. (2003) 
[139], Simmonds et al. (2007) [42] 
2q33 CTLA-4  Yanagawa et al. (1995) [27], Vaidya et al. (1999) [140], Ueda et al. (2003) [9], Furugaki et al. (2004) 
[141] 
1p13 PTPN22  Smyth et al. (2004) [69], Velaga et al. (2004) [70], Heward et al. (2007) [73] 
10p15  IL2R  Brand et al. (2007) [10] 
14q31  TSHR  Hiratani et al. (2005) [57], Dechairo et al. (2005) [56], Brand et al. (2009) [58] 
5q32 SCGB3A2  Song et al. (2009) [51], Simmonds et al. (2010) [65], Chistiakov et al. (2011) [52] 
20q13  CD40  Tomer et al. (2002) [89], Simmonds et al. (2005) [142], Houston et al. (2004) [87], Jacobson et al. 
(2005) [88], Jacobson et al. (2007) [143] 
1q22 FCRL3  Kochi et al. (2005) [97], Simmonds et al. (2006) [144], Owen et al. (2007) [145] 
8q24 Tg  Tomer et al. (2002) [86], Collins et al. (2003) [83], Collins et al. (2004) [84],  Tomer et al. (2004) [85]  
Implicated Risk Loci Requiring Confirmation  
2p25 TPO  Kotani et al. (1986) [146], Kotani et al. (1986) [147],  Ludgate et al. (1990) [148], Pirro et al. (1995) 
[149]  
2q24 IFIH1  Sutherland et al. (2007) [150], Todd et al. (2007) [103] 
14q31  DIO2  Chistiakov et al. (2004) [151] 
5q32 ADRB2  Chu et al. (2009) [64] 
1q23 FCGRIIa  Yesmin et al. (2010) [152] 
1p31 IL23R  Huber et al. (2008) [153] 
5q31 IL-3  Chu et al. (2009) [66], Simmonds et al. (2010) [169] 
5q31 IRF1  Yang et al. (2005) [61] 
6p21 PSMB8  Vives-pi et al. (1997) [154], Heward et al. (1999) [155] 
6p21 PSMB9  Vives-pi et al. (1997) [154], Heward et al. (1999) [155] 
2q37 PDCD1  Newby et al. (2007) [156] 
6p21 TNF  Simmonds et al. (2004) [157], Nakkuntod et al. (2006) [158] 
7q34 TCR- Demaine et al. (1989) [159], Pickerill et al. (1993) [160], Zhang et al. (2000) [161] 
Xp11  FOXP3  Owen et al. (2006) [91], Ban et al. (2007) [90] 
5q31 IL-13  Bednarczuk et al. (2003) [63], Hiromatsu et al. (2005) [162], Simmonds et al. (2005) [62] 
5q31 IL-4  Heward et al. (2001) [163], Yang et al. (2005) [61] 
2q13 IL-1RN  Blakemore et al. (1995) [164], Muhlberg et al. (1998) [165] 
6p21 LTA  Nakkuntod et al. (2006) [158] 
12q13 
8q23
VDR 
SAS-ZFAT 
Ban et al. (2000) [166], Ban et al. (2000) [167], Collins et al. (2004) [92], Ramos-Lopez et al. (2005) 
[93], Stefanic et al. (2005) [94] 
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diseases, AS and MS [96]. Disappointingly no other gene 
regions demonstrated genome-wide significance (P<10
-5 in a 
14,500 GWAS) although modest levels of significance were 
identified in several non-HLA regions (P<10
-4) [96]. Among 
these was a nsSNP within FCRL3 (P=2.1x10
-4), which had 
previously been implicated as a GD susceptibility locus in 
Japanese and Caucasian candidate gene studies [96]. The 
FCRL1-FCRL5 region on chromosome 1q23, encodes a 
number of FCRL genes that are known to control aspects of 
B cell signalling and were first identified as conferring 
susceptibility in RA [97]. Detailed SNP screening in RA had 
previously refined the association signal to four SNPs in 
FCRL3, which had subsequently been replicated in a 
Japanese GD cohort (n=351, P=7.4x10
-5) with some 
evidence for association in HT as well (n=158, P=0.02) [97]. 
To determine whether the signal identified in the nsSNP 
screen was due to LD with variants previously identified 
within FCRL3, seven tag SNPs were selected to screen the 
FCRL3-FCRL5 region in a cohort extended from 1,000 to 
2,500 GD cases and 2,500 58C controls [96]. Strongest 
evidence of association was identified within FCRL3 tag 
SNP rs11264798 (P=1.6x10
-5 OR=1.22) with less evidence 
of association in FCRL5  [96]. More recent association 
screening with logistic regression analysis across the entire 
FCRL3-FCRL5 region demonstrated that the aetiological 
variant is most likely to be within FCRL3 [98]. Since FCRL3 
nsSNPs demonstrated modest significance and was later 
confirmed as a GD susceptibility locus, other borderline 
signals in this study have since been investigated. In total 10 
nsSNPs demonstrated modest association (P<10
-5) with GD 
and were subsequently investigated in an independent GD 
cohort (1578 UK Caucasian GD and 1946 controls) [99]. 
None of the 10 nsSNPs demonstrated GD association in the 
independent cohort. However after combining the data from 
the nsSNP study, weak association (P 10
-3) was identified in 
HDLBP, TEKT1, JSRP1 and UTX  [99]. Subsequent 
additional tag SNPs selected within these four gene regions 
to refine the association signal, identified additional but 
modest SNP associations within two of the genes, HDLBP
and TEKT1 (P=10
-2-10
-3) [99]. These 4 genes are, therefore, 
unlikely to confer major GD risk, however smaller risks 
cannot be discounted. Further investigation of these genes in 
independent cohorts is now required to confirm AITD 
susceptibility at these loci. 
  An advantage of the WTCCC nsSNP study was that all 
individuals in the 4 disease cohorts and controls were from 
the same ethnic background (UK Caucasian), and therefore, 
an additional analysis was performed, which pooled the non-
AITD diseases (BC, AS and MS) and 58C together 
(combined controls n=4,500) to enlarge the reference control 
cohort [96]. This was based on the reasonable assumption 
that GD is likely to have at least some unique susceptibility 
loci from the other diseases. This analysis revealed the TSHR
nsSNP, rs3783941, conferred strongest evidence of 
association with GD (P=2.1x10
-5), confirming previous 
reports of TSHR susceptibility in GD [96]. The TSHR variant 
failed to reach even borderline significance (P=10
-3) in the 
original GD versus control analysis, although greater power 
from an enlarged control cohort enabled identification of the 
well-established  TSHR susceptibility locus [96]. This 
underlines the requirement for larger cohort sizes in GWAS. 
Despite identification of the TSHR, failure to identify other 
previously confirmed GD risk loci, such as PTPN22, CD40, 
IL2R  and SCGB3A2 reflects the lack of genome coverage in 
the nsSNP study. These genes may have been detected in a 
500k GWAS since it is more likely that a SNP in strong LD 
(r
2 0.80) with these regions would have been directly 
investigated. While nsSNP screens may still have value in 
providing a complimentary approach, detailed association 
screens investigating 500,000 SNPs or more is required to 
sufficiently screen the human genome for GD susceptibility 
loci. 
  Recent GWAS and meta-analysis’ combined with further 
replication in additional cohorts has so far identified over 40 
loci that affect risk to T1D [100]. The apparent sharing of 
susceptibility genes among autoimmune disease and the 
large number of risk regions now identified in T1D, 
prompted attempts to investigate these regions for 
association in GD. A follow-up study in T1D sought to 
investigate variants that demonstrated evidence of 
association, but below genome-wide significance (P<10
-7)
from 2 earlier GWAS; the first a 13,378 nsSNP screen in 
3,400 T1D cases and 3,300 controls [101] and the second a 
500k GWAS by the WTCCC in 2,000 T1D (as well as six 
other diseases) and 3,000 controls [102]. Using an 
independent T1D case-control (4,000 T1D cases and 5,000 
controls) and second parent-child trio (n=2,997) cohort, 
several regions demonstrated convincing evidence of T1D 
association, including; C12orf30 on chromosome 12q24, 
ERBB3 on 12q13, KIAA0350 on 16p13, PTPN2 on 18p11 
and  CD226 on 18q22 [103]. In total 13 genomic regions 
showed some evidence of replication in T1D and 
consequently were selected for analysis in 2,200 GD cases 
from the UK National collection with the same controls used 
in the T1D study [103]. Five regions demonstrated evidence 
of GD association with a single SNP investigated in each 
locus, these were; AFF3 on chromosome 2q11 (P=0.02, 
OR=1.10),  Tenr-IL2  on 4q27 (P=0.007, OR=0.87), CAPSL
on 5p13 (P=0.009, OR=0.88), PTPN2 on 18p11 (P=0.02, 
OR=1.13) and CD226 on 18q22 (P=0.01, OR=1.10) [103]. 
Further exon re-sequencing and tag SNP screening of CD226
in T1D and MS identified a potential aetiological variant at 
nsSNP Gly307Ser (rs763361), which also showed strong 
association in 2958 GD cases and 5431 controls (P=0.03, 
OR=1.08) [104]. In general, the magnitudes of association 
for novel GD loci are quite small, and therefore, these 
signals require further replication in independent GD 
cohorts. It should be noted that in T1D much larger case-
control cohorts were used to detect the association signals 
and as such much larger GD cohorts are likely to be required 
to provide more convincing evidence of association in GD. 
While these findings need further replication the data 
suggests these loci might be acting on shared autoimmune 
disease risk pathways. 
  Further work is ongoing to investigate loci identified in 
other autoimmune diseases for association in AITD. 
Determining disease pathways conferring susceptibility to 
autoimmunity in general, will provide novel insights into 
disease mechanisms and provide clues as to how specific 
autoimmune disorders like AITD develop. The WTCCC 
immunochip project, now underway, represents a major 
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genotyping array is investigating all common variants, in 
regions of the genome that have previously been implicated 
in one or more autoimmune disease, including; T1D, GD, 
MS, RA, AS and SLE. This will provide a much clearer 
picture of susceptibility locus sharing among the 
autoimmune diseases, including GD and within each 
associated region will provide a refined association map for 
further genetic and functional studies. 
COPY NUMBER VARIATIONS AND FUTURE 
DIRECTION IN GENETIC STUDIES 
  The human genome contains a diverse spectrum of 
genetic variation from SNPs to large, microscopically visible 
copy number variations (CNVs), which include 
insertion/deletions, duplications and complex re-
arrangements, ranging from >50bp to megabases (Mb) in 
size [105]. Since the majority of studies have focused on 
either SNPs or microsatellite markers, recent attention has 
turned to CNV analysis, to determine whether CNVs will 
provide novel disease association signals. A recent detailed 
genome screen of 3,432 CNVs were investigated in 3,000 
shared controls and eight diseases, including T1D, RA, CD, 
type 2 diabetes, hypertension, bipolar disorder, breast cancer 
and coronary artery disease [106]. Just 3 susceptibility loci 
among the four diseases were identified; TSPAN8 in type 2 
diabetes, IRGM in CD and the HLA region in T1D, RA and 
CD, all of which had previously been identified [106]. 
Furthermore, it was shown that common CNVs tend to be in 
strong LD with SNPs present in HapMap and GWAS, 
suggesting previous SNP screens will have captured the 
majority of common  genetic variation in nearby CNVs 
[106]. This suggests CNVs are unlikely to have utility in 
future screens for susceptibility loci in complex genetic 
diseases. However, fine-mapping studies require 
interrogation of all polymorphisms, including CNVs to 
identify an aetiological variant, and therefore, interrogation 
of CNVs in susceptibility regions is important [107]. The 
first CNV analysis in GD, recently investigated CNVs in the 
AITD risk regions, CTLA-4, CD40 and PTPN22 in 191 GD 
cases and 192 controls however no association of CNVs 
within these regions were identified [108]. Analysis of 
CNVs in other established AITD risk regions is now also 
required to determine whether CNVs have a role in 
susceptibility within these regions. 
  To date there are at least 10 confirmed AITD 
susceptibility loci with many more probable risk genes 
awaiting confirmation of association (Table 1). These have 
predominantly been identified by SNP screens of candidate 
regions and follow-up studies of novel genes identified in 
other autoimmune diseases, such as T1D. Despite the 
successes, it is likely only a small proportion of genetic risk 
factors for AITD have so far been identified. The two major 
challenges in AITD genetics include; continued screening 
for novel AITD susceptibility loci, with the first 500k 
GWAS in AITD anticipated, and second, fine-mapping of 
associated regions to identify the key aetiological variants, 
which could provide clues as to how AITD risk is conferred 
at a given locus. The genetics field is seeing unprecedented 
advances; in particular next generation sequencing platforms 
are transforming the speed and cost of whole genome 
sequencing. This has facilitated ambitious ventures such as 
the 1000 genomes project, which aims to characterise 95% 
of genetic variation down to allele frequencies of 1% by 
sequencing well over 1000 genomes in several populations 
[109]. Next generation sequencing technology has also been 
harnessed in techniques outside the realms of genome 
sequencing, including; genome-scale chromatin 
immunoprecipitation (ChIP) followed by sequencing (ChIP-
Seq) and whole exome RNA sequencing [110]. Chip-Seq 
data is providing detailed maps of transcription factor 
binding in multiple cell types and RNA-Seq will provide 
RNA transcript maps in many different cells and tissues, 
including those that are disease affected. Overlaying the 
many different types of data generated like Chip-Seq, onto 
association maps may help refine association signals and 
help to inform future functional studies in AITD.  
DISEASE MECHANISMS 
  The emerging genetic architecture of AITD reflects that 
of other autoimmune diseases, with the HLA class I and II 
regions demonstrating the greatest magnitude of risk to 
AITD with OR>2.0 [42, 43]. The second tier of loci, with 
OR 1.5, include CTLA-4 [9], PTPN22 [69] and TSHR [50, 
58], while the final group, such as FCRL3 [96, 98] and 
SCGB3A2 [51, 52, 65] exhibit more modest risk with 
OR=1.2-1.5. However, gene-gene interaction or epistasis and 
inevitably gene-environment interaction may modulate risk 
at individual gene regions. Improved knowledge of protein 
function encoded by AITD risk genes may help to answer 
questions of gene interaction, for example whether there are 
additive or multiplicative risks acquired when an individual 
possess a risk allele in two or more AITD predisposing 
genes. Although issues of interaction remain to be 
elucidated, a look at the AITD genes identified so far 
highlights a number of putative AITD disease mechanisms 
(Fig. 3). 
  The HLA class I and II genes encode heterodimers 
responsible for antigen presentation in many different cell 
types, including B cells, dendritic cells and macrophages. 
The DRB1, DQA1 and DQB1 genes belong to the HLA 
class II region and have been consistently associated with 
AITD [28, 43, 44]. The predisposing DR3 haplotype, 
DRB1*03-DQB1*02-DQA1*0501  and protective DR7
DRB1*07-DQB1*02-DQA1*0201 have consistently 
demonstrated strongest association with GD [28, 29]. 
Further association mapping has identified amino acid 
substitutions at position 74 of the DRB1 binding pocket, 
where arginine at 74 confers predisposition and glutamine 
protection [43, 44]. It is possible amino acid substitutions at 
binding pockets like DRB1-74 may increase the risk of 
antigen binding to self-antigens for presentation to CD4
+ T
cells [111, 112]. More recently, HLA class I genes 
demonstrated association independently of class II regions 
with HLA-C and to a lesser extent HLA-B showing strongest 
association [42]. The HLA class I genes bind endogenously 
derived peptides such as bacterial and viral antigens and 
present to CD8
+ T cells. This may implicate viral or bacterial 
infection as an environmental trigger of AITD, clearly 
however, further work is required to investigate this 
possibility.  
  The strong genetic association of GD autoantigens, Tg 
and particularly the TSHR, suggests these proteins may not 534 Current Genomics, 2011, Vol. 12, No. 8 Brand and Gough
Fig. (3). Pathways involved in AITD pathogenesis. The cell types and tissues believed to be involved in AITD pathogenesis.  The proteins 
expressed by the genes or regions in boxes are implicated in various cell functions indicated by arrows. Specifically, thyroid antigens, TSHR 
and Tg are autoantigenic targets in GD, they are also expressed in thymus possibly for the purpose of central tolerance of maturing 
thymocytes and may be presented by APCs to self-reactive T cells. HLA class I and II genes are expressed in many different cell types 
including B cells, dendritic cells and macrophages and bind antigens for presentation to T cells during central tolerance within the thymus and 
in the periphery. The IL2R , PTPN22 and CTLA-4 are primarily expressed on various subsets of T cells whereas SCGB3A2 and FCRL3 are 
known to be predominantly involved in B cell function.
just be victims of an immune system gone wrong but may 
trigger or exacerbate GD in people that are autoimmune 
predisposed. The TSHR undergoes extensive post-
translational processing resulting in an intracellular and 
transmembrane, B subunit, which is covalently bound to a 
large extracellular A subunit [113-115]. The A subunit is 
sometimes cleaved and shed from the membrane surface, 
which has been hypothesised to stimulate an autoimmune 
response, since the A subunit is the site of TSHR 
autoantibody binding, and recently characterised by X-ray 
crystallisation [55, 116]. Several studies have also 
characterised alternate TSHR mRNA transcripts, with two 
confirmed  truncated transcripts, 1.3Kb and 1.7Kb in size, 
encoding nearly the entire A subunit directly, which is the 
target of autoantigens in GD [117-119]. These transcripts 
now require further functional characterisation. Expression 
studies in a modest number of human thyroid tissue samples 
(n=12) demonstrated that GD predisposing variants within 
TSHR intron 1 increase mRNA of the 1.3Kb and 1.7Kb 
transcripts compared to flTSHR [58]. It is therefore possible 
that non-coding variants may increase the level of potentially 
autoantigenic A subunits, which stimulate an autoimmune 
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response in predisposed individuals. A similar scenario is 
well-established with the insulin gene (Ins) in T1D [120, 
121]. A Variable Number of Tandem Repeats (VNTR) 5’ of 
Ins that are predisposing to T1D cause an increase in mRNA 
expression of Ins within the pancreas but a reduction in 
thymus tissue [120]. The reduced expression in thymus may 
affect the education of maturing T cells to insulin, resulting 
in the production of insulin auto-reactive T cells in the 
periphery. Further TSHR expression studies with reference to 
GD associated genotypes in thymus tissue are required to 
investigate the possibility of a similar role in GD. It should 
be noted that peptide binding studies have shown that GD 
associated HLA class II variants are able to bind peptides 
belonging to TSHR and Tg proteins [111, 112]. These 
studies have however, not accounted for post-translational 
modifications or influences by other environmental factors 
on peptide antigenicity, which has been observed in other 
autoimmune diseases, such as citrullination of proteins in 
RA [122].  
  The T lymphocytes (T cells) have been implicated in 
AITD pathophysiology for a long time, with susceptibility 
genes, CTLA-4 and PTPN22 both expressed in various T cell 
subsets. CTLA-4 knock out (KO) mice exhibit fatal 
lymphocytic infiltration of multiple organs within the first 3-
4 weeks of life, suggesting CTLA-4 is involved in the 
control of lymphocyte activation and proliferation [123, 
124]. Previous studies suggested CTLA-4 functions via its 
APC ligands CD80 and CD86 to increase the activation 
threshold for self-antigens in Effector T cells [125, 126]. 
Although more recent studies in mice have demonstrated that 
CTLA-4 is also essential in regulatory T cell function (Treg) 
(Foxp3
+) where CTLA-4-deficient-Tregs have diminished 
ability to suppress APC mediated T cell activation [127]. 
Furthermore, CTLA-4 has been shown to play an important 
role in thymic development of Tregs, where CTLA-4 
deficiency causes an increased frequency of self-reactive 
Tregs in the periphery [128]. While CTLA-4 may have 
diverse functions in different cell types, recent studies have 
characterised at least one molecular mechanism, where 
CTLA-4 takes up and subsequently degrades CD80/CD86 
ligands by endocytosis from the APC surface in various T 
cell subsets including Tregs [129]. The CD80/86 ligands are 
shared by the T cell activator CD28, and therefore, depletion 
of ligands by CTLA-4, inhibits CD28 mediated T cell 
activation. Another example of this is PTPN22, which 
encodes the T cell signalling molecule LYP. LYP interacts 
with various cell signalling molecules, like Csk-kinase, c-
Cbl and Grb-2 to inhibit T cell activation [67, 130]. The 
R620W polymorphism is most likely the causal variant 
within this gene and it was assumed that the AITD 
associated LYP-TRP620 confers a loss of function in LYP, 
and therefore, a lower T cell activation threshold [68]. 
However, it has been demonstrated that the AITD associated 
LYP-TRP620 causes reduced activity of T cells and a lower 
expression of the T cell activation marker IL-2 following 
stimulation of TRP620 carrying T cells [131]. The LYP-
TRP620 variant has also demonstrated reduced activity in B 
cells thus also highlighting its role in other cell types [132]. 
Another T cell marker associated with GD is IL2R ; a key 
marker used to characterise CD4
+CD25
+Foxp3
+ T regs [74]. 
The role of IL-2R signalling in GD pathogenesis recently 
gathered further support, with association of the IL-2 gene 
region with GD [103]. In T1D, highly associated IL2R 
variants are also associated with lower levels of soluble 
IL2R protein [78]. While this remains to be investigated in 
GD, it is likely that aberrant polymorphisms in molecules 
involved in IL-2R signalling may predispose to GD, possibly 
by affecting Treg function or other T cell subsets. The 
various AITD susceptibility genes known to be involved in 
many aspects of T cell function, highlights a prominent role 
for T cell mediated pathways in GD pathogenesis. 
  The production of thyroid specific autoantibodies by 
auto-reactive B cells in AITD, obviously suggests a link to B 
cell mediated immune mechanisms. Recently there has been 
a growing number of AITD susceptibility genes associated 
with B cell biology, including; CD40 [87-89], SCGB3A2
[51, 52, 65] and FCRL3 [96-98]. Genetic variations in these 
genes may disrupt aspects of B cell function, such as cell 
signalling  via  FCRL3, leading to thyroid specific 
autoantibody production. While B cells were previously 
thought to primarily function as APCs and effector cells, 
there is emerging evidence of B cell involvement in adaptive 
immunity, particularly with the identification of regulatory B 
cells [133]. Indeed it has been shown that subgroups of B 
cells may regulate T cell activation and promote the 
proliferation of Tregs [134]. The improved understanding of 
B cell biology combined with the increasing number of 
AITD susceptibility loci expressed within these cells, may 
escalate future interest in B cells as a potential therapeutic 
target.  
CONCLUSIONS 
  The search for AITD susceptibility loci has evolved 
considerably over the years with the majority of risk genes 
identified or confirmed within the last decade. The field of 
genetics is currently undergoing a renaissance in terms of 
our understanding of human genetic architecture and our 
ability to screen for disease risk with ever more cost-
effective platforms. The future challenge in AITD genetics is 
to perform extensive surveys of genetic association across 
the entire spectrum of type and frequency of genetic 
variation. In the next few years we hope to possess a more 
complete picture of AITD genetic risk, which will 
undoubtedly bring new challenges. A more complete 
inventory of AITD risk genes will be vital to develop more 
precise disease-models of AITD pathogenesis, which in 
future might be translated to improve disease management.  
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